Europe’s medicines regulator has added an extremely rare nerve-damaging disorder, Guillain-Barré syndrome, as a possible side-effect of AstraZeneca’s COVID-19 vaccine.
This is what regular safety updates from the watchdog showed late on Wednesday.
The European Medicines Agency also said a causal relationship between GBS and the AstraZeneca shot, known as Vaxzevria, was a “at least a reasonable possibility” after 833 cases of GBS were reported out of 592 million doses of the vaccine given worldwide by July 31.
The EMA categorised the side-effect as “very rare”, the lowest frequency of side-effect category it has, and has emphasised that the benefits of the shot outweigh the risks.
(Reuters)